Studies of poly(ethylene glycol) modification of HM-3 polypeptides

Bioconjugate Chemistry

Volumn 20, Issue 5, 2009, Pages 932-936

  Zhou, Kang ^a   Zheng, Xiaoqing ^a   Xu, Han Mei ^a   Zhang, Jie ^a   Chen, Yaqing ^a   Xi, Tao ^a   Feng, Tingting ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE DERIVATIVE; ANGIOGENESIS INHIBITOR; ARGINYLGLYCYLASPARTIC ACID; HM 3; HM 3 PEPTIDE; MACROGOL; MACROGOL DERIVATIVE; PHOSPHATE BUFFERED SALINE; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; PEPTIDE;

AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CHICK EMBRYO; CHORIOALLANTOIS; CONTROLLED STUDY; DRUG DESIGN; DRUG HALF LIFE; DRUG PURIFICATION; EMBRYO; IN VITRO STUDY; IN VIVO STUDY; INCUBATION TIME; MALE; NONHUMAN; PH MEASUREMENT; PROTEIN MODIFICATION; RAT; REACTION ANALYSIS; REACTION TIME; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; ROOM TEMPERATURE; STOICHIOMETRY; ANGIOGENESIS; ANIMAL; BLOOD; CHEMISTRY; DRUG DEVELOPMENT; DRUG EFFECTS; DRUG STABILITY; ENZYME SPECIFICITY; HALF LIFE TIME; REPRODUCIBILITY; SPRAGUE DAWLEY RAT;

RATTUS;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; CHICK EMBRYO; DRUG DISCOVERY; DRUG STABILITY; HALF-LIFE; MALE; NEOVASCULARIZATION, PHYSIOLOGIC; PEPTIDES; POLYETHYLENE GLYCOLS; RATS; RATS, SPRAGUE-DAWLEY; REPRODUCIBILITY OF RESULTS; SUBSTRATE SPECIFICITY;

EID: 66149189321     PISSN: 10431802     EISSN: None     Source Type: Journal    
DOI: 10.1021/bc900070r     Document Type: Article

References (27)

1. Sorensen, D. R., Read, T.-A., and Porwol, T. (2002) Endostatin reduces vascularization, blood Xow and growth in a rat gliosarcoma. Neuro-Oncology. 4, 1-8. (Pubitemid 34269461)
2. Sudhakar, A., Sugimoto, H., and Yang, C. (2003) Human tumstatin and human endostatin exhibit distinct antiangiogenic activities mediated by αVβ3 and α5β1 integrins. Proc. Natl. Acad. Sci. U.S.A. 100, 4766-4771 (Pubitemid 36457804)
3. Rehn, M., Veikkola, T., and Kukk-Valdre, E. (2001) Interaction of endostatin with integrins implicated in angiogenesis. Proc. Natl. Acad. Sci. U.S.A. 98, 1024-1029 (Pubitemid 32121180)
4. Ding, Y. H., Javaherian, K., and Lo., K. M. (1998) Zinc-dependent dimmers observed in crystals of human endostatin. Proc. Natl. Acad. Sci. U.S.A. 95, 10443-10448
5. Boemhm, T., O'Reilly, M. S., Keough, K., Shiloach, J., Shapiro, R., and Folkman., J. (1998) Zinc-binding of endostatin is essential for its antiangiogenic activity. Biochem. Biophys. Res. Commun. 252, 190-194
6. Sasaki, T., Fukai, N., Mann, K., Goring, W., Olsen, B. R., and Timpl, R. (1998) Structure, function and tissue forms of the C-terminal globular domain of collagen XVIII containing the angiogenesis inhibitor endostatin. EMBO J. 17, 4249-4256 (Pubitemid 28362615)
7. Dhanabal, M., Volk, R., Ramchandran, R., Simons, M., and Sukhatme, V. P. (1990) Cloning, expression, and in vitro activity of human endostatin. Biochem. Biophys. Res. Commun. 258, 345-352.
8. O'Reilly, M. S., Boehm, T., and Folkman, J. (1997) Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88, 277-285. (Pubitemid 28015876)
9. Dhanabal, M., Ramchandran, R., Volk, R., Stillman, E. I., Lombardo, M., Iruela-Arispe, M. L., Simons, M., and Sukhatme, P. V. (1999) Endostatin: yeast production, mutants, and antitumor eVect in renal cell carcinoma. Cancer Res. 59, 189-197. (Pubitemid 29062977)
10. You, W. K., So, S. H., Lee, H., Park, S. Y., Yoon, M. R., Chang, S. L., Kim, H. K., Joe, Y. A., Hong, Y. K., and Chung, S. I. (1999) Purification and characterization of recombinant murine endostatin in E. coli. Exp. Mol. Med. 31, 197-202. (Pubitemid 30021337)
11. Wickstrom, S. A., Alitalo, K., and Keski-Oja, J. (2004) An endostatin-derived peptide interacts with integrins and regulates actin cytoskeleton and migration of endothelial cells. J. Biol. Chem. 279, 20178-20185 (Pubitemid 38623462)
12. Robert, M., Sjin, T. T., Satchi-Fainaro, R., Birsner, A. E., Ramanujam, V. M. S., Folkman, J., and Javaherian, K. (2005) A 27-Amino-Acid synthetic peptide corresponding to the NH2-teminal zinc-binding domain of endostatin is responsible for its antitumor activity. Cancer Res. 659, 3656-3663 (Pubitemid 40616342)
13. Cattaneo, M. G., Pola, S., Francescato, P., Chillemi, F., and Vicentini, L. M. (2003) Human endostatin-derived synthetic peptides possess potent antiangiogenic properties in vitro and in vivo. Exp. Cell Res. 283, 230-236 (Pubitemid 36269028)
14. Chillemi, F., Francescato, P., Ragg, E., Cattaneo, M. G., Pola, S., and Vicentini, L. (2003) Studies on the structure-activity relationship of endostatin: synthesis of human endostatin peptides exhibiting potent antiangiogenic activities. J. Med. Chem. 46, 4165-4172 (Pubitemid 37122458)
15. Morbidelli, L., Donnini, S., Chillemi, F., Giachetti, A., and Ziche, M. (2003) Angiosuppressive and angiostimulatory effects exerted by synthetic partial sequences of endostatin. Clin. Cancer Res. 9, 5358-5369 (Pubitemid 37413591)
16. Cho, H., Kim, W. J., Lee, Y. M., Kim., Y. M., Kwon, Y. G., Park, Y. S., Choi, E. Y., and Kim, K. W. (2004) N-/C-terminal deleted mutant of human endostatin efficiently acts as an antiangiogenic and anti-tumorigenic agent. Oncol. Rep. 11, 191-195
17. Zitzmann, S., Ehemann, V., and Schwab, M. (2002) Arginine-Glycine- Aspartic Acid RGD;-peptide binds to both tumor and tumor-endothelial cells in vivo. Cancer Res. 62, 5139-5143
18. Arap, W., Pasqualini, R., and Ruoslahti, E. (1998) Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 279, 377-380. (Pubitemid 28063372)
19. Xu, H. M., Yin, R. T., Chen, L. S., Siraj, S., Huang, X. F., Wang, M., Fang, H. S., and Wang, Y. (2008) An RGD-modified endostatin-derived synthetic peptide shows antitumor activity in vivo. Bioconjugate Chem. 19, 1980-1986
20. Roberts, M. J., Bentley, M. D., and Harris, J. M. (2002) Chemistry for peptide and protein PEGylation. Adv. Drug Delivery Rev. 54, 459-476. (Pubitemid 34615543)
21. Caliceti, P., and Veronese, F. M. (2003) Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugate. Adv. Drug Delivery Rev. 55, 1261-1277. (Pubitemid 37464561)
22. Lee, S. H., Lee, S., Youn, Y. S., Na, D. H., Chae, S. Y., Byun, Y., and Lee, K. C. (2005) Synthesis, charaterization, and pharmacokinetic studies of PEGylated glucagon-like peptide-1. Bioconjugate Chem 16, 377-382. (Pubitemid 40388214)
23. Na, D. H., Youn, Y. S., Park, E. J., Lee, J. M., Cho, O. R., Lee, K. R., Lee, S. D., Yoo, S. D., DeLuca, P. P., and Lee, K. C. (2004) Stability of PEGylated salmon calcitonin in nasal mucosa. J. Pharm. Sci. 93, 256-261. (Pubitemid 38174248)
24. Na, D. H., Park, M. O., Choi, S. Y., Kim, Y. S., Lee, S. S., Yoo, S. D., Lee, H. S., and Lee, K. C. (2001) Identification of the modifying sites of mono-PEGylated salmon calcitonins by capillary electrophoresis and MALDI-TOF mass spectrometry. J. Chromatogr., B 754, 259-263. (Pubitemid 32241091)
25. Roberts, M. J., Bentley, M. D., and Harris, J. M. (2002) Chemistry for peptide and protein PEGylation. Adv. Drug Delivery Rev. 54, 459-476. (Pubitemid 34615543)
26. Kinstler, O. B., Brems, D. N., Lauren, S. L., Paige, A. G., Hamburger, J. B., and Treuheit, M. J. (1996) Characterization and stability of N-terminally PEGylated rhG-CSF. Pharm. Res. 13, 1724-1734
27. Kinstler, O., Molineux, G., Treuheit, M., Ladd, D., and Gegg, C. (2002) Mono-N-terminal poly(ethylene glycol)-protein conjugates. Adv. Drug Delivery Rev. 54, 477-485 (Pubitemid 34615544)